11LU013
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 59.21149897
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- ANGIOGENESIS+0.320
- CHOLESTEROL_HOMEOSTASIS+0.230
- NOTCH_SIGNALING+0.200
- ANDROGEN_RESPONSE+0.140
- OXIDATIVE_PHOSPHORYLATION+0.140
- GLYCOLYSIS+0.100
- APICAL_JUNCTION+0.090
- FATTY_ACID_METABOLISM+0.070
- HEDGEHOG_SIGNALING+0.070
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.320
- ALLOGRAFT_REJECTION-0.290
- P53_PATHWAY-0.290
- TNFA_SIGNALING_VIA_NFKB-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.230
- INTERFERON_GAMMA_RESPONSE-0.200
- MITOTIC_SPINDLE-0.190
- PANCREAS_BETA_CELLS-0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.190
- APOPTOSIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG841 | — | — | 0.669 |
| 2 | e2ac493b-9157-4756-8949-edf4b7f334cd | — | — | 0.667 |
| 3 | 733aa64f-0d61-4f6a-8353-0299d4678704 | — | — | 0.647 |
| 4 | 204241b7-1e28-43f8-a681-f872b52fa3f8 | — | — | 0.638 |
| 5 | TCGA-69-7979-01A-11R-2187-07 | — | cohortA1 | 0.637 |
| 6 | SRR6013521 | — | cohortA1 | 0.636 |
| 7 | MBCproject_0036_T1_RNA | — | C | 0.635 |
| 8 | BSR_19_0079_A1_S53 | — | B | 0.623 |
| 9 | MNG740 | — | — | 0.622 |
| 10 | TCGA-BH-A18K-01A-11R-A12D-07 | — | C | 0.622 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |